TB-500 (Thymosin Beta-4): what the research actually shows
For me, used alongside BPC-157 for a shoulder injury, it worked. That is personal, not evidence.
Why I looked into this
TB-500 has a specific shape of hype around it. Equine athletes first, human biohackers second, gym-floor stories third. The thread is always the same: tendons, ligaments, recovery. I wanted to know whether the published human record backed any of that.
It does not. What exists in humans is a small, focused, sponsor-funded research program on full Thymosin Beta-4 for unrelated indications, which is a different claim than what most people buying TB-500 think they are buying.
What TB-500 actually is
Thymosin Beta-4 is a naturally occurring 43-amino-acid protein found in almost every mammalian tissue. It is an intracellular actin-sequestering protein with roles in cell migration, angiogenesis, and inflammatory signaling when released extracellularly.
“TB-500” as sold in gray markets is typically either synthetic full TB-4 or an unverified fragment. The commercial name and the peptide that has actually been studied in humans are not always the same molecule.
What the human research shows
Do published human trials exist?
Yes, a small number. RegeneRx Biopharmaceuticals ran roughly four sponsor-funded Phase 2 trials of full synthetic TB-4 (RGN-259) across dry eye, venous ulcers, and an acute MI pilot using ex-vivo cell pre-treatment. Total participants across studied indications are under 250. None of the programs advanced to Phase 3.
What did those trials actually show?
- Sosne et al. 2015, Cornea. Phase 2 placebo-controlled RCT of RGN-259 topical eye drops for severe dry eye. Reported improved ocular discomfort and reduced corneal staining vs vehicle at day 56. RegeneRx-funded.
- Guarnera et al. 2007, Ann NY Acad Sci. Dose-escalation RCT of topical TB-4 in venous ulcers. Interim safety paper; full efficacy data never published in a peer-reviewed venue.
- Crockford 2007, Ann NY Acad Sci. Phase 1 review describing IV TB-4 in 40 healthy volunteers, no dose-limiting toxicity at studied levels.
- Zhu et al. 2016, Cytotherapy. Small pilot in STEMI patients using ex-vivo TB-4 pre-treated cells, not systemic TB-4 administration.
What the research does not show in humans
- Not shown to heal muscle injuries
- Not shown to heal tendon or ligament injuries
- Not shown to improve flexibility or recovery in athletes
- Not shown to regrow hair
- No Phase 3 data for any indication, no FDA approval for any indication
- No evidence that the “TB-500” fragment sold in gray markets has the same activity as full TB-4
Known safety signals in humans
The published Phase 1 and Phase 2 work generally reported good tolerability at studied doses. No serious adverse events were clearly attributed to TB-4 in the small trials that have been published. Long-term human safety data does not exist.
There is a biologically plausible theoretical concern: TB-4 promotes angiogenesis, and angiogenesis is a feature of both healing and tumor growth. This has not been studied in humans. Community reports mention occasional injection-site reactions and fatigue, which are uncontrolled anecdotes.
FDA and legal status in the US
No approved human indication exists. The July 23, 2026 PCAC meeting will review TB-500 specifically for wound healing as a proposed 503A addition. The committee can vote either way.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal is harm reduction, not facilitation. I do not name vendors. I do not link to sellers.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable address
- Willing to specify whether product is full TB-4 or a fragment
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- Will not clarify full TB-4 vs unverified fragment
- Sells Category 2 substances for human use
The wrinkle for TB-500 specifically
TB-500 sold online is often not the same molecule as full Thymosin Beta-4 studied in the published trials. That alone breaks the chain of evidence people assume they are buying into.
Cost reality
A compounded peptide made at a legitimate pharmacy carries a real cost for identity verification, sterility, and third-party testing. Pricing far below that almost always reflects missing quality steps.
Questions worth asking any source
Is the pharmacy 503A-licensed? Can they provide a COA? Is the product full TB-4 or a fragment, and which fragment? Where is the physical facility? A legitimate operation will answer without hesitation.
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide alongside BPC-157. Your situation is not my situation.
For me, TB-500 worked. I used it alongside BPC-157 for the same shoulder injury I mentioned in that monograph. The combination resolved the pain over about a month and I got full function back.
What I can say is that the combination matched the thing I wanted, which was to stop babying the shoulder and get back to training. Whether BPC-157 was the active ingredient, TB-500 was, rest was, or some combination of all of them, I do not know. I am not pretending the anecdote is a trial.
My view on TB-500 specifically is that the marketed use (muscle and tendon healing) is not what the published trials actually studied. The trials that do exist studied dry eye and ulcers. That is an honest thing to say out loud.
If I had to choose one of the two for a future injury, I would probably reach for BPC-157 first on cost and access grounds, and consider adding TB-500 only if the injury was not responding. That is a personal judgment, not a recommendation, and it assumes a legitimate pathway that does not exist right now.
Questions to ask your doctor
If you are considering TB-500, or you are already using it and want an honest conversation with a clinician, these are the questions I would bring.
- Given that the published human trials of TB-4 studied dry eye and venous ulcers, not muscle or tendon injury, how would you interpret the evidence base for my specific use?
- Are there FDA-approved alternatives for my injury or condition that we should try first?
- If I proceed despite the evidence gap, what would you monitor and how often?
- Is there a way to verify whether what I have access to is full TB-4 or a fragment?
- What interactions should I be aware of with any medications I am currently taking?
- What would change your view on TB-500, and what signals would you want me to report?
What to do next
Read the BPC-157 monograph
Same evidence-framework, same source-safety framing. The two peptides are frequently discussed together.
Open BPC-157 →Download the visit-prep packet
Walk into your next appointment with the human-evidence summary and the six questions above.
Get the packet →Work through the 503A checklist
My evergreen source-safety checklist. Use it on any peptide source you are evaluating.
Open the checklist →Sources
- Sosne et al. 2015. Cornea, 34(5):491-6. Phase 2 placebo-controlled RCT, RGN-259 in severe dry eye. RegeneRx-funded.
- Sosne & Ousler 2015. Clinical Ophthalmology, 9:877-84. Phase 2 controlled environment RCT in dry eye. RegeneRx-funded.
- Guarnera et al. 2007. Ann NY Acad Sci, 1112:407-12. Prospective RCT of topical TB-4 in venous ulcers.
- Crockford 2007. Ann NY Acad Sci, 1112:385-95. Phase 1 safety review, 40 healthy volunteers.
- Zhu et al. 2016. Cytotherapy, 18(8):1037-42. STEMI pilot, ex-vivo cell treatment.
- FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
- Federal Register, April 16, 2026. PCAC meeting notice, docket FDA-2025-N-6895.
- WADA Prohibited List 2026, S2 category.
Sources are provided so the reader can read the primary evidence. Inclusion does not imply endorsement of the claims made in any cited work.
Related monographs
BPC-157
Same review cycle, same source-safety constraints. Often discussed together with TB-500.
MOTS-c
Endogenous levels measured in humans, zero trials of exogenous administration.
FDA review July 2026
Seven peptides, two days, one docket. What the meeting means and what it does not.